Home | Our Ovarian Cancer Test | Evident Ovarian Cancer Screening Test

Evident Ovarian Cancer
Screening Test

Early Ovarian Cancer Detection Is Finally Within Reach
with the Evident Ovarian Cancer Screening Test

Woman with her dog at the beach

Evident is designed for postmenopausal women

at average risk as part of their routine annual health check. It offers women a dependable option to integrate early ovarian cancer detection into their standard preventive care.

An annual blood test

is a reliable solution, detecting previously hidden, early-stage ovarian cancer when it is most treatable

Actionable information

enables empowered health choices and provides peace of mind 

A new standard of care

can now be included with other routine blood work and screenings

Early Detection
and Unmatched Accuracy 

Evident is a simple blood test provides accurate screening results with: 

Doctor Talking with a Female Patient
0  %
Specificity
0  %
Sensitivity

in detecting stage I and II high-grade serous carcinoma (HGSC) ovarian cancer, the most common and deadly type of ovarian cancer1

Early detection can boost five-year survival from ~17% in advanced disease to ~90% in stage I patients2

woman meditating to relax

Science-Led, Patient-First

Built on rigorous clinical evidence and designed with patients and physicians at the center, Evident identifies ovarian cancer with proprietary EV technology. Discover the science behind Evident.

The Testing

Process

Evident offers clarity and confidence—leading to timely, informed decisions and expanded options when further care is needed. See how the Evident screening test process works.

Smiling woman out on the town

Reference Notes:

  1. Manning B, Banerjee S, Hawkins T, et al. Extracellular vesicle and particle-based blood test for ovarian cancer of average risk population: a promising nested case-control study using preclinical samples. Gynecol Oncol. 2025;203:26-34. doi:10.1016/j.ygyno.2025.10.003 
  2. SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute; July 2, 2025. Accessed November 19, 2025. Available at: https://seer.cancer.gov/statistics-network/explorer/